News

Researchers identified a previously hidden RNA molecule that regulates cholesterol production by activating SREBP2, a key metabolic regulator. Blocking this RNA lowered cholesterol and reduced atherosclerosis in mice.

Scripps Research chemists developed a one-step, stereoselective method to add fluorine to drug-like molecules using inexpensive fluoride salts, overcoming a decades-old challenge and enabling faster drug development and PET imaging.

Discover how a new library enhances drug exposure records via untargeted metabolomics data, revealing hidden medication impacts.

An analysis of 341 pivotal US drug trials found that only 6% reflected the nation’s racial and ethnic makeup, with Black and Hispanic participation declining since 2021. The findings raise concerns for precision medicine and drug safety.

A large US database study suggests GLP-1 receptor agonists may be associated with a reduced risk of developing epilepsy in people with type 2 diabetes. Compared with DPP-4 inhibitors, GLP-1 drugs were linked to a 16% lower risk.

By designing a squaric acid amide that binds a new site on ATP synthase, researchers created PRP020, a potential therapy for bedaquiline-resistant tuberculosis. The compound is effective, stable and safe in cell models.

New psychoactive substances, linked to adverse side effects, may still offer pharmaceutical promise with new research on receptor interactions that utilizes deep learning and large-scale computer simulations.

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it produced high remissions in CD123-positive AML and as monotherapy, it delivered high responses in high-risk BPDCN patients.

Researchers have identified existing compounds that block the coronavirus Mpro enzyme, including a potent molecule called 5b. These candidates show low toxicity and may lead to new treatments for emerging, drug-resistant variants.

A world-first base-edited CAR-T therapy has helped previously untreatable for T-cell acute lymphoblastic leukemia patients achieve remission, with 82% responding and many now disease-free.